TCF Theracryf Plc

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Result of AGM and Investor Presentation

Alderley Park, UK - 18 July 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, held its AGM today and all resolutions were passed.  The AGM voting results are available on the Company's website Here.

-Ends-

Enquiries

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy* [*orphan indications]. Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid‐size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and University of Connecticut.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF.

For further information, please visit: www.theracryf.com.